| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0360-3016(96)00468-3 |
| P698 | PubMed publication ID | 9054871 |
| P50 | author | Timothy E. Schultheiss | Q55603219 |
| P2093 | author name string | W R Lee | |
| M A Hunt | |||
| G E Hanks | |||
| A L Hanlon | |||
| R S Peter | |||
| P2860 | cites work | Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. | Q34417137 |
| Acute toxicity during external-beam radiotherapy for localized prostate cancer: comparison of different techniques. | Q40869390 | ||
| Causes and consequences of inhomogeneous dose distributions in radiation therapy | Q41467997 | ||
| Models in radiotherapy: volume effects. | Q52704118 | ||
| The Relationship of Reactions to Complications in the Radiation Therapy of Cancer of the Cervix | Q53781573 | ||
| Dose escalation for stage C (T3) prostate cancer: minimal rectal toxicity observed using conformal therapy | Q57619993 | ||
| Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a significant dose effect | Q60153383 | ||
| Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer | Q60153389 | ||
| Conformal static field therapy for low volume low grade prostate cancer with rigid immobilization | Q68194173 | ||
| Prognostic factors in carcinoma of the prostate--analysis of RTOG study 75-06 | Q68961841 | ||
| A ten year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States | Q68961889 | ||
| Effect of latency on calculated complication rates | Q69619800 | ||
| Importance of predisposing factors in the development of enteric damage | Q70388367 | ||
| Analysis of the probability and risk of cause-specific failure | Q71646037 | ||
| Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate | Q72333657 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 3-11 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | International Journal of Radiation Oncology Biology Physics | Q2296252 |
| P1476 | title | Late GI and GU complications in the treatment of prostate cancer | |
| P478 | volume | 37 |
| Q85174856 | A Method for the Prediction of Late Organ-at-Risk Toxicity After Radiotherapy of the Prostate Using Equivalent Uniform Dose |
| Q90066228 | A multi-disciplinary model of survivorship care following definitive chemoradiation for anal cancer |
| Q58229293 | A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis |
| Q77308142 | A practical method to achieve prostate gland immobilization and target verification for daily treatment |
| Q52057681 | A variable critical-volume model for normal tissue complication probability. |
| Q59364454 | Acute Toxicity of Conventional Radiation Therapy for High-Risk Prostate Cancer in EORTC Trial 22863 |
| Q79242551 | Acute and late genitourinary toxicity of conformal radiotherapy for prostate cancer |
| Q33177749 | Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study |
| Q93948514 | Acute radiation proctitis |
| Q33924822 | Acute radiation proctitis: a sequential clinicopathologic study during pelvic radiotherapy |
| Q44146815 | Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: longer term follow-up of a phase III trial--Trans-Tasman Radiation Oncology Group |
| Q53063040 | Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: nonrandomized comparison with conventional fractionation. |
| Q43364496 | Approaches to the prevention and management of radiation colitis |
| Q43340330 | Chronic effects of therapeutic irradiation for localized prostatic carcinoma on anorectal function |
| Q40898354 | Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. |
| Q30862749 | Clinical use of stereoscopic X-ray positioning of patients treated with conformal radiotherapy for prostate cancer |
| Q43125022 | Comparison of rectal volume definition techniques and their influence on rectal toxicity in patients with prostate cancer treated with 3D conformal radiotherapy: a dose-volume analysis |
| Q41649061 | Conformal proton therapy for early-stage prostate cancer |
| Q77463835 | Conformal proton therapy for prostate carcinoma |
| Q40130646 | Consequential late effects after radiotherapy for prostate cancer - a prospective longitudinal quality of life study |
| Q34455126 | Consequential late effects in normal tissues |
| Q48736026 | Conventionally Fractionationed Volumetric Arc Therapy versus Hypofractionated Stereotactic Body Radiotherapy: Quality of Life, Side Effects, and Prostate-Specific Antigen Kinetics in Localized Prostate Cancer |
| Q73770991 | Cost-benefit analysis of 3D conformal radiation therapy |
| Q60153374 | Daily CT localization for correcting portal errors in the treatment of prostate cancer |
| Q39489072 | Diabetes mellitus: a predictor for late radiation morbidity |
| Q89553062 | Diagnosis and Management of Non-Variceal Gastrointestinal Hemorrhage: A Review of Current Guidelines and Future Perspectives |
| Q35040098 | Distinct effects of rectum delineation methods in 3D-conformal vs. IMRT treatment planning of prostate cancer. |
| Q49041065 | Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer |
| Q38810088 | Dosimetric impact in the dose-volume histograms of rectal and vesical wall contouring in prostate cancer IMRT treatments |
| Q44909902 | Early hyperbaric oxygen therapy improves outcome for radiation-induced hemorrhagic cystitis |
| Q34725046 | Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence |
| Q43276195 | Effect of a prostaglandin--given rectally for prevention of radiation-induced acute proctitis--on late rectal toxicity. Results of a phase III randomized, placebo-controlled, double-blind study |
| Q50934122 | Efficacy of a belly board device with CT-simulation in reducing small bowel volume within pelvic irradiation fields. |
| Q85104318 | Endoscopic Ultrasonographic Features of Subacute Radiation Proctitis |
| Q41833224 | Endoscopic findings of rectal mucosal damage after pelvic radiotherapy for cervical carcinoma: correlation of rectal mucosal damage with radiation dose and clinical symptoms |
| Q41833449 | Endoscopic treatments for chronic radiation proctitis |
| Q36364403 | Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment |
| Q47141907 | Factors Predicting Late Rectal Disorders after Radiation Therapy for Prostate Cancer |
| Q73718033 | Factors determining acute normal tissue reactions during postoperative radiotherapy in endometrial cancer: analysis of 317 consecutive cases |
| Q36541173 | Gastrointestinal radiation injury: symptoms, risk factors and mechanisms |
| Q37780019 | Gastrointestinal toxicity associated to radiation therapy |
| Q35584836 | Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer. |
| Q81452950 | HIV impact on acute morbidity and pelvic tumor control following radiotherapy for cervical cancer |
| Q24170223 | Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from CaPSURE |
| Q36726326 | High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients |
| Q33867039 | Histopathological comparison of topical therapy modalities for acute radiation proctitis in an experimental rat model |
| Q43787131 | Hyperbaric oxygen--an effective tool to treat radiation morbidity in prostate cancer. |
| Q33294811 | Image-guided helical tomotherapy for localized prostate cancer: technique and initial clinical observations |
| Q50941550 | Impact of a rectal and bladder preparation protocol on prostate cancer outcome in patients treated with external beam radiotherapy. |
| Q33496347 | Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment |
| Q75211168 | Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy |
| Q48958679 | Impact of the target volume (prostate alone vs. prostate with seminal vesicles) and fraction dose (1.8 Gy vs. 2.0 Gy) on quality of life changes after external-beam radiotherapy for prostate cancer |
| Q52021801 | Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy. |
| Q30814522 | Initial clinical experience with infrared-reflecting skin markers in the positioning of patients treated by conformal radiotherapy for prostate cancer. |
| Q41841932 | Intensity Modulated Radiation Therapy Reduces Gastrointestinal Morbidity in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer |
| Q53164682 | Intensity-Modulated Radiotherapy Reduces Gastrointestinal Toxicity in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer |
| Q73428333 | Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis |
| Q52659989 | Inter-institutional analysis demonstrates the importance of lower than previously anticipated dose regions to prevent late rectal bleeding following prostate radiotherapy. |
| Q46681328 | Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). |
| Q81049787 | Is hormone therapy a protective factor for late hematuria after high-dose radiotherapy in prostate cancer? |
| Q73006980 | Is there a role for short-term hormone use in the treatment of nonmetastatic prostate cancer? |
| Q58229282 | Is there more than one late radiation proctitis syndrome? |
| Q63365946 | Late gastrointestinal toxicity after radiation for prostate cancer |
| Q52068692 | Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. |
| Q73661195 | Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response |
| Q34238364 | Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model |
| Q59651014 | Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer |
| Q89869735 | Linking CHHiP prostate cancer RCT with GP records: A study proposal to investigate the effect of co-morbidities and medications on long-term symptoms and radiotherapy-related toxicity |
| Q34678605 | Localized prostate cancer. |
| Q35123271 | Localized prostate cancer: radiation or surgery? |
| Q34677997 | Locally advanced prostate cancer |
| Q35936700 | Long-term (10-year) gastrointestinal and genitourinary toxicity after treatment with external beam radiotherapy, radical prostatectomy, or brachytherapy for prostate cancer |
| Q34098732 | Long-term prognosis in patients with severe late radiation enteropathy: a prospective cohort study |
| Q73045365 | Long-term urinary toxicity after 3-dimensional conformal radiotherapy for prostate cancer in patients with prior history of transurethral resection |
| Q24235544 | Low-dose rate brachytherapy for men with localized prostate cancer |
| Q75209403 | Lower gastrointestinal bleeding |
| Q44369883 | Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy |
| Q46160400 | Neoadjuvant hormonal therapy and external-beam radiotherapy versus external-beam irradiation alone for prostate cancer. A quality-of-life analysis |
| Q55554370 | PTV margin for dose escalated radiation therapy of prostate cancer with daily on-line realignment using internal fiducial markers: Monte Carlo approach and dose population histogram (DPH) analysis. |
| Q77110431 | Partial boosting of prostate tumours |
| Q41727433 | Particle beam radiation therapy in prostate cancer: is there an advantage? |
| Q36617012 | Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects |
| Q52067202 | Planning, computer optimization, and dosimetric verification of a segmented irradiation technique for prostate cancer. |
| Q60177887 | Potential role of intensity modulated proton beams in prostate cancer radiotherapy |
| Q48022836 | Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localised prostate cancer: a phase 2 study |
| Q33830800 | Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. |
| Q75200315 | Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate |
| Q33804697 | Progress in 3D conformal radiation treatment of prostate cancer |
| Q74487342 | Prostate cancer: low alpha/beta the only consideration? In regard to Fowler, Chappell, and Ritter: the prospects for new treatments for prostate cancer |
| Q34455133 | Quantification of late complications after radiation therapy |
| Q35870610 | Radiation dose-volume effects in radiation-induced rectal injury |
| Q36655284 | Radiation dose-volume effects of the urinary bladder |
| Q34572064 | Radiation for prostate cancer. |
| Q34284907 | Radiation injury of the rectum |
| Q39448990 | Radiation proctitis: current strategies in management |
| Q74068042 | Radiation therapy as treatment for stage T1c prostate cancers |
| Q34252146 | Rating general practitioner consultation performance in cancer care: does the specialty of assessors matter? A simulated patient study |
| Q60232877 | Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer |
| Q73677003 | Rectal dose sparing with a balloon catheter and ultrasound localization in conformal radiation therapy for prostate cancer |
| Q36812625 | Rectourethral fistula after combination radiotherapy for prostate cancer. |
| Q39415628 | Reducing radiation-associated toxicity using online image guidance (IGRT) in prostate cancer patients undergoing dose-escalated radiation therapy |
| Q77712029 | Relationship between acute and late normal tissue injury after postoperative radiotherapy in endometrial cancer |
| Q74710145 | Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions |
| Q73153888 | Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer |
| Q60048825 | Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action |
| Q36295691 | Salvage image-guided intensity modulated or stereotactic body reirradiation of local recurrence of prostate cancer. |
| Q50248563 | Salvage radiotherapy after high-intensity focused ultrasound for localized prostate cancer: early clinical results |
| Q42437496 | Secondary effects and biochemical control in patients with early prostate cancer treated with (125)-I seeds. |
| Q35777339 | Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. |
| Q28304984 | Sodium butyrate enemas in the treatment of acute radiation-induced proctitis in patients with prostate cancer and the impact on late proctitis. A prospective evaluation |
| Q58229267 | Spontaneous improvement in late rectal mucosal changes after radiotherapy for prostate cancer |
| Q53593229 | Stereotactic IMRT for prostate cancer: dosimetric impact of multileaf collimator leaf width in the treatment of prostate cancer with IMRT. |
| Q38384072 | Supporting patients treated for prostate cancer: a video vignette study with an email-based educational program in general practice |
| Q34728366 | Systematic review for non-surgical interventions for the management of late radiation proctitis |
| Q73203855 | The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer |
| Q58656934 | The contribution of the cone beam Kv CT (CBKvCT) to the reduction in toxicity of prostate cancer treatment with external 3D radiotherapy |
| Q38266168 | The evolution of rectal and urinary toxicity and immune response in prostate cancer patients treated with two three-dimensional conformal radiotherapy techniques. |
| Q77157440 | The influence of interpatient and intrapatient rectum variation on external beam treatment of prostate cancer |
| Q33183151 | The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial |
| Q47944425 | The treatment of nonpalpable PSA-detected adenocarcinoma of the prostate with 3-dimensional conformal radiation therapy |
| Q73332671 | Therapeutic outcome and relation of acute and late side effects in the adjuvant radiotherapy of endometrial carcinoma stage I and II |
| Q77963050 | Three dimensional conformal photon radiotherapy at a moderate dose level of 66 Gy for prostate carcinoma: early results |
| Q73850855 | Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison |
| Q86508042 | Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus |
| Q85125251 | Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer |
| Q41994836 | Toxicity of tomotherapy-based simultaneous integrated boost in whole-pelvis radiation for prostate cancer |
| Q38611189 | Toxicity report of once weekly radiation therapy for low-risk prostate adenocarcinoma: preliminary results of a phase I/II trial |
| Q34500966 | Transitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: changing focus from rectal bleeding to detailed quality of life analysis |
| Q36614896 | Treatment- and disease-related complications of prostate cancer. |
| Q77476258 | Update on the treatment of prostate cancer with external beam irradiation |
| Q33728655 | Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. |
| Q35768827 | Volumetric modulated arc therapy in prostate cancer patients with metallic hip prostheses in a UK centre |
| Q74547651 | [Indications and results of exclusive radiotherapy in early prostatic adenocarcinoma] |
| Q77291684 | [Intestinal lesions from radiotherapy] |
| Q52994860 | [Locally advanced prostate carcinoma (T2b-T4 N0) without and with clinical evidence of local progression (Tx N+) with lymphatic metastasis. Is radiotherapy for pelvic lymphatic metastasis indicated or not?]. |
Search more.